[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study — Michael S. Hofman (2018) | RDL Network
[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, A. Antón, Roslyn Wallace, Anupama Pasam, Mathias Bressel, E. Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski,
Discussion(0)
No comments yet. Be the first to comment.